Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 5 6 4

+8 more TTM periods

ROE
(146.27%) (355.31%) (473.47%) (155,671.52%)
ROA
(41.90%) 58.47% 47.54% 30.34%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(223.41%) 249.03% 248.32% 171.64%
Average Days of Receivables
102.13 175.25 159.41 2,460.67
Free Cash Flow per Share
(1.20) (1.25) (1.18) (0.78)
Free Cash Flow
(186.03) (170.57) (138.51) (90.19)
Other line items
Cash ROIC
(91.46%) (60.31%) (51.27%) (28.51%)
Accounts Receivable Turnover
0.76 1.10 0.60 0.17
Accounts Payable Turnover
0.62 0.57 0.72 0.54
Inventory Turnover
3.11 3.59 3.74 0.50
Average Days of Payables
303.77 279.79 261.98 725.77
Days of Inventory on Hand
130.73 117.60 83.81 59.71
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
198.70% 226.25% 258.20% 265.56%
Selling, General and Administrative Expense of Revenue
181.79% 208.35% 238.56% 286.90%
Share Based Compensation of Revenue
21.87% 29.82% 40.23% 55.35%
Interest Coverage
(17.47) (19.02) (20.12) (24.15)
Operating CF/Net income
1.41 (0.92) (0.82) (0.58)
Depreciation/Fixed assets
4.17 3.44 2.92 2.49
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.33 0.34 0.36 0.32
Operating CF per Share
(1.20) (1.25) (1.18) (0.78)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates